GSK press releases Follow Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) Application based on data from positive GLISTEN phase III trial https://www.gsk.com/en-gb/media/press-releases/linerixibat-new-drug-application-nda-accepted-for-review-by-the-us-fda/ gsk.com
